Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 31, 2022
Reporting Period: The filing addresses a specific event occurring on August 31, 2022, regarding the company's stock listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a listing deficiency and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the receipt of a written notice from Nasdaq indicating that the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days (July 20, 2022, through August 30, 2022). This constitutes a failure to satisfy Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted a 180-day compliance period, ending February 27, 2023, to regain compliance with the Minimum Bid Price Requirement.
- Path to Compliance: Compliance can be achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days during the compliance period.
- Contingencies: If compliance is not achieved by the deadline, the Company may be eligible for an additional compliance period if it meets other initial listing standards (excluding the bid price) and notifies Nasdaq in writing.
- Management Action: Management intends to actively monitor the bid price and is considering available options to regain compliance, including effecting a reverse stock split.
- Immediate Impact: The notice has no immediate effect on the listing or trading of the common stock; it continues to trade under the symbol "ADIL."
Investor Verification Checklist
- Verify the current closing bid price of ADIL stock to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to cure the deficiency.
- Track the stock price performance over the next 10 consecutive business days to determine if automatic compliance is achieved.
- Review future filings for updates on the status of the compliance period as the February 27, 2023, deadline approaches.